OpGen Inc. is back in compliance with Nasdaq’s rules, but CEO Evan Jones says the Gaithersburg biotech must do a better job helping the market recognize its value. The molecular diagnostics company (NASDAQ: OPGN) staved off its third delisting threat in the last year after making a number of financial moves, including a 1-for-25 reverse stock split to help increase its share price above Nasdaq’s $1-per-share minimum, one of the issues that put OpGen at risk. OpGen also priced a $12 million public…
from https://www.bizjournals.com/baltimore/news/2018/02/06/opgen-regains-nasdaq-compliance-but-wall-street.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/170572415337
No comments:
Post a Comment